TJX:NYSETJX Companies, Inc. (The) Analysis
Data as of 2026-05-27 - not real-time
$156.78
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
TJX delivered a strong earnings beat with revenue up 9.2% YoY to $61.6 B and EPS climbing to $5.13, while management raised FY 2027 guidance and lifted the dividend to $1.92 per share, reflecting a 33% payout ratio and a 27.5% five‑year dividend growth rate. Operating margins remain healthy at 11.8% and free cash flow exceeds $4.3 B, supporting the impressive 61% ROE and a robust balance sheet with ample cash. Analyst sentiment is bullish, with a “strong buy” consensus and a median price target near $176, implying roughly 13% upside.
On the technical side, the stock trades just above its 20‑day SMA (≈$153.8) and near the 50‑day SMA (≈$156.6), with a neutral RSI of 53 and a bullish MACD histogram. Volume is increasing, and the MACD signal turned bullish, suggesting short‑term momentum could push the price toward the $160.9 resistance. However, the DCF fair value of $67 indicates the market is currently overvalued, so investors should weigh the valuation gap against the strong fundamentals and dividend sustainability.
On the technical side, the stock trades just above its 20‑day SMA (≈$153.8) and near the 50‑day SMA (≈$156.6), with a neutral RSI of 53 and a bullish MACD histogram. Volume is increasing, and the MACD signal turned bullish, suggesting short‑term momentum could push the price toward the $160.9 resistance. However, the DCF fair value of $67 indicates the market is currently overvalued, so investors should weigh the valuation gap against the strong fundamentals and dividend sustainability.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD histogram with increasing volume
- Price trading just below resistance at $160.9
- Neutral RSI indicating no immediate overbought pressure
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Strong revenue growth (9.2%) and EPS beat
- Raised FY 2027 guidance and dividend increase
- Valuation still above DCF fair value, limiting upside
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustained high ROE (61%) and solid free cash flow generation
- Consistent dividend growth and sustainable payout ratio
- Competitive off‑price retail model with resilient consumer demand
Key Metrics & Analysis
Financial Health
Revenue Growth9.20%
Profit Margin9.40%
P/E Ratio30.6
ROE61.25%
ROA13.87%
Debt/Equity136.31
P/B Ratio17.0
Op. Cash Flow$7.6B
Free Cash Flow$4.3B
Technical Analysis
TrendNeutral
RSI53.6
Support$146.14
Resistance$160.89
MA 20$153.76
MA 50$156.65
MA 200$150.29
MACDBullish
VolumeIncreasing
Fear & Greed Index91.91
Valuation
Fair Value$67.26
Target Price$177.63
Upside/Downside13.30%
GradeOvervalued
TypeGrowth
Dividend Yield1.21%
Risk Assessment
Beta0.30
Volatility23.58%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.